Wetherby Asset Management Inc. increased its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,987 shares of the company’s stock after acquiring an additional 1,859 shares during the period. Wetherby Asset Management Inc.’s holdings in Eli Lilly and were worth $1,603,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Pathstone Family Office LLC raised its stake in Eli Lilly and by 100.0% during the 2nd quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after buying an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. acquired a new stake in shares of Eli Lilly and in the 2nd quarter valued at about $494,000. Gradient Investments LLC acquired a new stake in shares of Eli Lilly and in the 4th quarter valued at about $103,000. Acrospire Investment Management LLC raised its stake in shares of Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the period. Finally, MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and in the 2nd quarter valued at about $128,000. Institutional investors and hedge funds own 77.58% of the company’s stock.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 9,625 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the completion of the sale, the senior vice president now owns 152,120 shares in the company, valued at approximately $12,339,974.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Donald A. Zakrowski sold 860 shares of the stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $76.50, for a total transaction of $65,790.00. The disclosure for this sale can be found here. Insiders sold a total of 12,261 shares of company stock worth $987,485 in the last 90 days. 0.20% of the stock is currently owned by company insiders.
Shares of Eli Lilly and Co (NYSE:LLY) opened at $79.15 on Wednesday. The company has a market cap of $86,596.06, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 1.47 and a beta of 0.28. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. Eli Lilly and Co has a 1 year low of $73.69 and a 1 year high of $89.09.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The company had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. During the same quarter in the prior year, the firm earned $0.95 EPS. The business’s revenue was up 7.0% on a year-over-year basis. equities research analysts expect that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.